Pyrrole Derivatives Targeting Peripheral CB1 Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current 4,5-diarylpyrrole-2-carboxamide derivatives with affinity for CB1 cannabinoid receptors have limited therapeutic potential due to high brain penetration, which can lead to central nervous system side effects, and there is a need for compounds with antagonistic properties specifically targeting peripheral CB1 receptors with reduced brain penetration.
Innovation Solution
Development of new 4,5-diarylpyrrole-2-carboxamide derivatives with specific substituents that minimize brain penetration, featuring a particular aryl group substitution pattern, allowing for targeted antagonism of peripheral CB1 receptors while maintaining therapeutic efficacy with reduced central nervous system activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 4,5-diarylpyrrole-2-carboxamide derivatives with affinity for CB1 cannabinoid receptors are used, then therapeutic efficacy is improved, but brain penetration increases leading to central nervous system side effects
Solution Approach 1:
The patent applies local quality by introducing specific substituent patterns at particular positions on the aryl groups of the pyrrole core. By modifying only specific regions of the molecule (local changes to R1, R2, R3-R8 substituents) while maintaining the overall CB1 receptor binding capability, the compound achieves selective peripheral action with reduced central nervous system penetration, thereby resolving the contradiction between therapeutic efficacy and side effects
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters such as substituent types, positions, and electronic properties on the pyrrole-2-carboxamide scaffold. These parameter modifications alter the pharmacokinetic profile of the compounds, specifically reducing brain penetration while preserving peripheral CB1 antagonism, thus achieving the desired balance between efficacy and safety
2Reliability
If compounds with high CB1 receptor affinity are developed, then therapeutic potential is enhanced, but selectivity between peripheral and central CB1 receptors decreases
Solution Approach 1:
The invention applies local quality by introducing specific hydrophobic and electronic substituents at defined positions on the aryl groups. These localized modifications create steric and electronic environments that favor interaction with peripheral CB1 receptors while reducing affinity for central receptors, thereby achieving both high therapeutic potential and improved receptor selectivity
Data Source
AI summary
The subject of the invention is compounds corresponding to the formula (I): in which: - R1 represents a hydrogen atom or a (C1-C4)alkyl group; - R2 represents a homopiperidin-1-yl, piperidin-1-yl, pyrrolidin-1-yl or azetidin-1-yl radical, or an amino (C1-C6)alkyl group; - or R1 and R2, together with the nitrogen atom to which they are attached, constitute a piperazin-1-yl, 1,4-diazepan-1-yl, homopiperidin-1-yl, piperidin-1-yl, pyrrolidin-1-yl or azetidin-1-yl radical; - one of the two substituents R3, R6 represents a Y-A-R9 group; - Y represents an oxygen atom, or an -S(O)n-, -OSO2- or-N(R18)- group; ‑ A represents an unsubstituted (C1-C4)alkylene group; - R9 represents an -OR12, -CN, ‑CO2H, NR12R13, -CONR12R13, -NR15COR12,-CONHNH2, -CONHOH, -CONHSO2R14, ‑S(O)nR14, -SO2NR12R13, -NR18SO2R14, or-NR15SO2NR12R13 group, or an aromatic heterocycle. The present invention also relates to the methods of preparation and the therapeutic applications of the compounds of formula (I) as cannabinoid CB1 receptor antagonists.